The Centers for Disease Control and Prevention holds patents on the use of Truvada for HIV prevention, according to advocates, who want Gilead Sciences to pay future and retroactive royalties to make PrEP more widely available.
The U.S. Food and Drug Administration this week approved Dovato, a two-drug combination pill that provides a complete once-daily antiretroviral regimen for people starting HIV treatment for the first time.
A bill to make it easier for people to access PrEP via their local pharmacy survived its first committee vote April 8 after California lawmakers amended it to restrict the supply of the HIV prevention medication to one month.
An Australian man said he acquired HIV while taking on-demand PrEP before and after sex, which could represent the latest in a handful of cases of failure of the prevention pill.
Around 80 percent of new HIV infections are attributable to people who either do not know their status or are not receiving treatment to suppress viral load, according to a new report from the Centers for Disease Control and Prevention.
PrEP was a major topic at the Conference on Retroviruses and Opportunistic Infections this month in Seattle. Researchers showed that a new version of tenofovir works as well as the Truvada pill and offered insights about how gay and bisexual men are using
Project Inform, one of the nation's longest-running HIV education and advocacy organizations, has terminated its staff and is likely to cease operations, the Bay Area Reporter has learned.
A London man with long-term undetectable HIV despite stopping antiretroviral treatment a year and a half ago could potentially be the second case of an HIV cure, according to a report at the Conference on Retroviruses and Opportunistic Infections.
Dr. Anthony Fauci of the National Institute of Allergy and Infectious Diseases fleshed out a proposed national HIV plan at the opening session of the Conference on Retroviruses and Opportunistic Infections this week in Seattle.
As health officials continue to urge more people at risk of becoming HIV-positive to take PrEP, the once-a-day pill that widely protects against being infected with the virus if taken as prescribed, San Francisco leaders are embracing a new dosing regimen
The number of people taking PrEP rose by nearly 30 percent from 2016 to 2017, but disparities remain, according to updated figures released this week by AIDSVu.
San Francisco will receive a grant from the Centers for Disease Control and Prevention to help close gaps and mitigate barriers in HIV prevention and care services, particularly among homeless people.
A San Francisco man is the sixth known case of PrEP failure despite consistent use of Truvada, researchers from the Department of Public Health and UCSF reported at the IDWeek conference held in San Francisco earlier this month.
